Table 1 Patient characteristics

Age > 60 years

56 (10.8)

17 (11.1)

0.010

0.911

37 (9.5)

17 (11.1)

0.052

0.649

Body mass index, kg/m²

22.6 (20.4, 25.1)

22.8 (20.7, 25.3)

0.038

0.748

22.6 (20.3, 25.1)

22.8 (20.7, 25.3)

0.026

0.917

Female sex, n (%)

211 (40.7)

66 (43.1)

0.050

0.584

159 (41.0)

66 (43.1)

0.044

0.744

Diabetes, n (%)

156 (30.1)

32 (20.9)

0.211

0.027

92 (23.7)

32 (20.9)

0.067

0.406

Hypertension, n (%)

457 (88.1)

140 (91.5)

0.114

0.234

346 (89.2)

140 (91.5)

0.079

0.432

Antihypertensive medication, n (%)

407 (78.4)

138 (90.2)

0.328

0.001

339 (87.4)

138 (90.2)

0.090

0.430

Cerebrovascular disease, n (%)

16 (3.1)

3 (2.0)

0.072

0.587

11 (2.8)

3 (2.0)

0.057

0.534

Congestive heart failure, n (%)

22 (4.2)

0 (0)

0.298

0.010

0 (0.0)

0 (0)

N/A

N/A

Ischemic heart disease, n (%)

29 (5.6)

8 (5.2)

0.016

0.864

18 (4.6)

8 (5.2)

0.027

0.652

Revised cardiac risk index, n (%)

0.232

0.060

0.066

0.930

 0

410 (79.0)

134 (87.6)

331 (85.3)

134 (87.3)

 1

92 (17.7)

16 (10.5)

48 (12.4)

16 (10.5)

 2

17 (3.3)

3 (2.0)

9 (2.3)

3 (2.0)

Echocardiographic parameters^a

 LVEF, %

62 (57, 66)

63 (59, 67)

0.325

0.021

63 (58, 67)

63 (59, 67)

0.224

0.017

 LVMI, g/m²

117.2 (99.3, 145.0)

100.9 (89.4, 128.5)

0.455

 < 0.001

117.62 (99.9, 147.5)

100.9 (89.4, 128.5)

0.466

 < 0.001

 LAVI, ml/m²

39.3 (31.4, 48.9)

36 (29.8, 42.3)

0.363

0.006

39.75 (32, 48.8)

36 (29.8, 42.3)

0.364

 < 0.001

 E/A ratio

0.94 (0.71, 1.2)

0.92 (0.74, 1.32)

0.109

0.334

0.95 (0.7, 1.2)

0.92 (0.74, 1.32)

0.085

0.290

 Deceleration time, m/sec

222 (193.8, 261.0)

225.6 (205.1, 252.3)

0.040

0.443

220.1 (192.1, 261.0)

225.6 (205.1, 252.3)

0.048

0.567

 E', m/sec

0.07 (0.06, 0.08)

0.08 (0.06, 0.1)

0.325

 < 0.001

0.07 (0.06, 0.09)

0.08 (0.06, 0.1)

0.239

0.005

 E/E' ratio

10 (8, 13)

8.31 (6.6, 10.3)

0.619

 < 0.001

9.95 (8.0, 12.4)

8.3 (6.6, 10.3)

0.592

 < 0.001

 TR velocity (m/sec)

2.4 (2.2, 2.6)

2.24 (2.1, 2.4)

0.529

 < 0.001

2.4 (2.2, 2.7)

2.2 (2.1, 2.4)

0.554

 < 0.001

Left ventricular hypertrophy, n (%)

300 (64.4)

56 (42.1)

 < 0.001

227 (65.0)

56 (42.1)

0.473

 < 0.001

Systolic dysfunction, n (%)

0.319

0.055

0.223

0.150

 LVEF ≥ 60%

299 (64.2)

96 (71.6)

229 (59.0)

96 (52.7)

 50% ≤ LVEF < 60%

138 (29.6)

37 (27.6)

108 (27.8)

37 (24.2)

 40% ≤ LVEF < 50%

17 (3.6)

1 (0.7)

7 (1.8)

1 (0.7)

 LVEF < 40%

12 (2.6)

0 (0)

5 (1.3)

0 (0)

Diastolic dysfunction, n (%)^b

0.484

 < 0.001

0.430

 < 0.001

 Indeterminate

50 (10.7)

5 (3.7)

121 (31.2)

44 (28.8)

 Grade 1

177 (38)

44 (32.6)

38 (9.8)

5 (3.3)

 Grade 2

92 (19.7)

18 (13.3)

72 (18.6)

18 (11.8)

 Grade 3

5 (1.1)

0 (0)

1 (0.3)

0 (0.0)

Preoperative plasmapheresis for ABOi KT

93 (17.9)

25 (16.3)

0.042

66 (17)

25 (16.3)

0.018

0.858

Modality of renal replacement therapy, n (%)

N/A

N/A

N/A

N/A

 Hemodialysis

473 (91.1)

0 (0)

351 (90.5)

 Peritoneal dialysis

46 (8.9)

0 (0)

37 (9.5)

Duration of renal replacement therapy, months

6 (2, 34)

0 (0, 0)

N/A

N/A

5.03 (1.7, 29.0)

N/A

N/A

Operation time, min

183 (155, 213)

174 (151, 216)

0.093

0.405

184 (155, 213)

174 (151, 216)

0.097

0.422

Baseline Cr, mg/dL

7.7 (5.7, 10.2)

7.5 (6.4, 9.2)

0.089

0.980

8.1 (6, 10)

7.5 (6.4, 9.2)

0.081

0.295